Skip to main content
OpenTrials
Completed

NCT Number: NCT06828705

Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride Camera

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU NANCY Brabois, nuclear medicine department

Vandœuvre-lès-Nancy, 54511, France

About this study

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

There are several types of cameras allowing its performance:

  • Conventional Anger cameras and,
  • CZT (Cadmium-Zinc-Telluride) semiconductor cameras. At the Nancy University Hospital, the nuclear medicine department has a wide-field Cadmium-Zinc-Telluride camera: VERITON-CT (Spectrum Dynamics). The interpretation of this examination is purely visual.

The objectives are therefore to:

  • Create the first international database of semi-quantitative values in 3D scintigraphy with Datscan performed with a VERITON-CT camera.
  • Compare this database with another database from a conventional Anger camera (Lyon Nuclear Medicine Department) to show its superiority.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients who have undergone a Datscan scintigraphy on the VERITON camera in the nuclear medicine department of the Nancy University Hospital and who have an established clinical diagnosis, -Absence of neurodegenerative pathology or Parkinson's disease or Lewy body disease.
  • The clinical diagnosis can only be established after two years of clinical follow-up.

Exclusion criteria

  • Excluded from this research will be the patients opposed to the use of their data, minors, atypical Parkinsonian syndromes,
  • patients who died before two years of clinical follow-up,
  • patients who had their Datscan examination carried out on a camera other than the VERITON and - patients lost to follow-up.

Treatment and study plan

datscan scintigraphy

Other

Semi-quantitative analysis on Datscan imaging scintigraphy

Primary outcomes

  1. To create the first international database of Datscan by camera VERITON-CT.

    Time frame: One day

    Fixation ratio of central gray nuclei of the brain namely, the global striatum, caudate nuclei, putamens

Secondary outcomes

  1. Compare this database with another database from another type of camera (Lyon nuclear medicine team) to show its superiority.

    Time frame: One day

    Identical to the primary evaluation criterion compared to those of the Lyon database.

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)

Acronym: DaTBase

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 14, 2025
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.